Evonik's Leadership and New Dividend Policy Signal Confidence Amid Restructuring

Evonik executives invest €130k+ as stock surges 21%. Analysts upgrade targets citing methionine market support, new dividend policy, and strategic savings plan.

Senior executives at German specialty chemicals group Evonik have made significant personal investments in the company's stock, a move interpreted by the market as a strong vote of confidence. Board member Dr. Claudine Mollenkopf and supervisory board member Dr. Cornelius Baur invested over €130,000 in late March, purchasing shares at levels around €16.40. This insider buying activity precedes the company's first-quarter earnings report and coincides with a series of analyst upgrades.

The stock has already gained more than 21 percent on a monthly basis, trading at €17.25. Several major banks have recently raised their price targets. Goldman Sachs and ODDO BHF both lifted their targets to €20.00, with ODDO BHF assigning an "Outperform" rating. Barclays increased its target to €17.00 with an "Overweight" rating, also raising its EBITDA estimate for 2026. Deutsche Bank, maintaining a more cautious "Hold," raised its target to €15.00.

Fundamental improvements in key markets are driving this optimism. The methionine amino acid market is providing unexpected support due to supply outages among Asian producers, which is forcing global buyers to reorient and driving up prices in Europe and China. Evonik has also implemented significant price increases in its Advanced Technologies segment. Analysts suggest European producers like Evonik could benefit from tight precursor supplies.

Concurrently, the company has laid out a new financial framework following its 2025 results. While annual sales declined 7 percent to €14.1 billion, net income improved to €265 million from €222 million. Adjusted EBITDA for 2025 reached €1.87 billion, coming in slightly below the forecast of approximately €1.9 billion but within the expected range. For 2026, management continues to target an adjusted EBITDA between €1.7 and €2.0 billion.

A major shift was announced in February regarding shareholder returns. Starting with the 2026 financial year, Evonik will adopt a new dividend policy, planning to distribute between 40 and 60 percent of its adjusted net income. This offers greater financial flexibility than the previous policy. For 2025, the board will propose a dividend of €1.00 per share at the Annual General Meeting on June 3, representing a yield of roughly 7 percent.

The company's strategic overhaul, dubbed "Evonik Tailor Made," remains on track. The program aims to achieve annual savings of €400 million by the end of 2026, a process that includes cutting up to 2,000 jobs globally. A key structural strength is the firm's significant local production in the United States, where approximately 80 percent of products sold are also manufactured. This insulates the US business, which accounts for 30 percent of total group sales, from potential trade policy disruptions.

Growth efforts in Asia were highlighted at the recent CHINAPLAS 2026 trade fair in Shanghai. Evonik showcased new products including VESTAKEEP® Easy Slide 2, a tribological high-performance PEEK polymer designed for plain bearing applications under extreme temperatures and high pressure, targeting sectors like mechanical engineering, medical technology, and robotics. Evonik's China head, Xia Fuliang, emphasized the role of local research and cross-industry collaboration in the region's industrial transformation.

The immediate focus now shifts to the upcoming quarterly report on May 8. Deutsche Bank Research anticipates an 18 percent year-on-year decline in first-quarter EBITDA to €461 million, citing margin pressure and currency effects. This report will serve as an initial test for management's full-year guidance. The market will be watching closely to see how the contrasting forces of operational headwinds and strategic tailwinds balance out when the figures are released.